Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

More DME competitive bidding planned. AdvaMed outlines strategic plan. Roche ends Illumina bid, for now.

You may also be interested in...



News Briefs: MAKO Purchase; KCI Merger; Medicare Competitive Bidding Update

MAKO plans to acquire Pipeline Biomedical Holdings before it becomes part of Stryker. KCI, LifeCell and Systagenix to merge. Medicare announces rates for DME competitive bidding recompete. More news.

Medicare Durable Equipment Cuts Will Deepen In Next Round Of Competitive Bidding

Starting July 1, Medicare plans to pay 45 percent less than current fee-schedule rates for eight categories of DMEPOS in 91 cities, and 72 percent less nationwide for diabetes products.

News In Brief

Merit snaps up Thomas Medical. Halma buys MicroSurgical Technology. Sanofi settles Hyalgan charges. More news briefs.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Diagnostics Reform Reintroduced in House

News We’re Watching: SALSA Reintroduced, FDA Approves Abbott Valve, Metallic Implant Study

Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year

Global Medtech Guidance Tracker: March 2023

See All
UsernamePublicRestriction

Register

MT031161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By